- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Novel Hepatitis C Vaccine Induces T Cell Responses
Science Translational Medicine
Adenovirus-based vaccines can generate strong, broad, long-lasting, and functional T cell responses against hepatitis C virus (HCV) in healthy people, according to a study published in the Jan. 4 issue of .
Eleanor Barnes, M.D., of the University of Oxford in the United Kingdom, and colleagues used a recombinant adenoviral vector strategy in a phase 1 trial of an HCV vaccine in healthy human volunteers. Two adenoviral vectors expressing NS proteins from HCV genotype 1B were constructed based on rare serotypes (human adenovirus 6 and chimpanzee adenovirus 3).
The researchers found that both of the vectors primed T cell responses against HCV proteins.
Read more at: http://www.physiciansbriefing.com/Article.asp?AID=660393
Source: HealthDay
HIV, Hepatitis C Testing Rates Remain Dismal Among Injection Drug Users
April 17th 2020Despite being at an increased risk for HIV and hepatitis C, persons who inject drugs (PWID) are tested at dismal rates for both: just 8.6% and 7.7%, respectively, according to data from 2010 to 2017. PWID who live in rural communities are more likely to face barriers to adequate testing and care for both diseases.
Read More
Dr Rebekah Gee Offers an Inside Look at Louisiana's Subscription Payment Model for HCV Drugs
May 7th 2019We speak with Dr Rebekah Gee, secretary of the Louisiana Department of Health about the subscription payment model for hepatitis C virus drugs that the state has entered into with Asegua Therapeutics, a subsidiary of Gilead Sciences.
Listen
